Sven Moosmang

Company: Boehringer Ingelheim
Job title: Therapeutic Area Head Translational Medicine & Clinical Pharmacology Cardiometabolism
Seminars:
Panel Discussion: How can we Modernize Surrogate Endpoint Development? Moving Beyond Hard Endpoints 8:00 am
Evaluating novel surrogate endpoints in addition to emerging standard of care Non-invasive imaging, patient-reported outcomes, UACR, and more: what is an acceptable endpoint? Considering payers perspectives’ on moving beyond hard endpoints and ESRDRead more
day: Day One